Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
01/10/2026 06:15
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Oct 1 (Reuters) - French drugmaker Sanofi SASY.PA said on Thursday it would pay US partner Regeneron REGN.O $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind their blockbuster eczema drug Dupixent.
The companies said they had settled earlier litigation over the collaboration and that they would split costs and profits of the expanded partnership equally.
(Reporting by Hugo Lhomedet in Gdansk, editing by Milla Nissi-Prussak)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement